Shots:
- Absci Corporation & Invetx have entered into a strategic collaboration to develop an innovative Half-Life Extension platform for animal health
- The alliance will leverage Absci’s generative AI models to develop modular antibody sequences in animals, while Invetx gains rights to use HLE platform for improving therapeutic effect duration & customer convenience of various products. The deal includes R&D funding, election fees, milestones & royalties on a per-product basis
- The goal is to address unmet needs in animal health, starting with canines and potentially expanding to other companion animals
Ref: Absci | Image: Absci & Invetx
Related News:- AstraZeneca Received the US FDA’s Approval for Truqap (capivasertib) + Fulvestrant to Treat the Patient with Advanced HR-Positive Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
